National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix E: Prospects for Immunizing Against Cytomegalovirus." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
234
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Plotkin, S.A. 1983. Personal communication, Children’s Hospital, Philadelphia, Penn.

Plotkin, S.A., H.M.Friedman, S.E.Starr, M.L.Smiley, R.G.Grossman, and C.Barker. 1983. The prevention of cytomegalovirus disease. Pp. 257–276 in Human Immunity to Viruses, F.A.Ennis, ed. New York: Academic.

Plotkin, S.A., M.L.Smiley, H.M.Friedman, S.E.Starr, G.R.Fleisher, C.Wlodaver, D.C.Dafoe, A.D.Freidman, R.A.Grossman, and C.F. Barker. 1984. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet I(8376):528–530.

Polk, B.F. 1983. Personal communication, Johns Hopkins University, Baltimore, Md.

Rook, A.H., and J.V.Quinnan. 1982. Cytomegalovirus infections following blood transfusion. Pp. 45–61 in Infectious Complications of Blood Transfusions, E.Tabor, ed. New York: Academic.

Scharschmidt, B. 1984. Personal communication. University of California, San Francisco.

Sherlock, S. 1983. Hepatic transplantation: The state of play. Lancet II(8353):778–779.

Stagno, S., D.W.Reynolds, R.F.Pass, and C.A.Alford. 1980. Breast milk and the risk of cytomegalovirus infection. N. Engl. J. Med. 302(19):1073–1076.

Stagno, S., R.F.Pass, M.E.Dworsky, and C.A.Alford. 1983. The nature of maternal cytomegalovirus infection and its consequences for the infant. Pp. 219–239 in Human Immunity to Viruses, F.A. Ennis, ed. New York: Academic.

Stewart, J. 1983. Personal communication. Centers for Disease Control, Atlanta, Ga.

Weller, T.H. 1971. The cytomegalovirus: ubiquitous agents with protein clinical manifestations. N. Engl. J. Med. 285:267–274.

White, F.M. Infectious mononucleosis. 1980. Pp. 166–168 in public Health and Preventive Medicine, J.M.Last, ed. New York: Appleton-Century-Crofts.

Whitley, R.J. 1984. Personal communication, University of Alabama, Birmingham.

Young, J.L., C.L.Percy, A.J.Asire, J.W.Berg, M.M.Cusano, L.A. Gloeckler, J.W.Horm, W.I.Lourie, E.S.Pollack, and E.M. Shambaugh. 1981. Surveillance, epidemiology, and end results: incidence and mortality data, 1973–1977. Natl. Cancer Inst. Monogr. 57:1–1081.

Page
234
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)